ClinicalTrials.Veeva

Menu
C

CenExel Clinical Research | CBH Health

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

SEP-363856
Esketamine
KarXT
BHV-7000
Rapastinel
Ralmitaront
Cariprazine
Aticaprant
Risperidone
RO6889450

Parent organization

This site is a part of CenExel Clinical Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 56 total trials

A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults

The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-...

Enrolling
COVID-19
Biological: CVXGA (CVXGA50)
Biological: COMIRNATY®

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disea...

Enrolling
Alzheimer Disease
Drug: Xanomeline Enteric Capsule
Drug: Xanomeline/Trospium Chloride Capsule

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Active, not recruiting
Depressive Disorder, Major
Drug: Aticaprant

This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, inpatient study in participants with bipolar disorder experiencing an a...

Enrolling
Bipolar Disorder Type I With Mania or Mania With Mixed Features
Drug: KarXT
Other: Placebo

The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on...

Enrolling
Depressive Disorder, Major
Drug: JNJ-89495120
Drug: Placebo

An Extension study to a clinical study that will continue to evaluate the effectiveness and safety of SEP-363856 in people with schizophrenia that sw...

Invitation-only
Schizophrenia
Drug: SEP-363856

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compul...

Active, not recruiting
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)

Active, not recruiting
Major Depressive Disorder
Drug: BHV-7000
Drug: Placebo

Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)

Active, not recruiting
Treatment Resistant Depression
Drug: Psilocybin

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).

Invitation-only
Major Depressive Disorder
Drug: BHV-7000

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Otsuka logo
Allergan logo
Biohaven logo
Merck Sharp & Dohme (MSD) logo
Roche logo
AbbVie logo
R
Biohaven logo
Bristol-Myers Squibb (BMS) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems